热门资讯> 正文
Axsome Therapeutics从Avenue Therapeutics收购Baergic Bio
2025-11-06 21:50
- Avenue Therapeutics (OTC:ATXI) agreed to sell its majority-owned subsidiary Baergic Bio to Axsome Therapeutics (AXSM).
- The deal includes global rights to BAER-101 (AZD7325), now renamed AXS-17, a GABAA α2,3 subtype-selective PAM for potential epilepsy treatment.
- Axsome gains worldwide commercial, development, and manufacturing rights to AXS-17.
- Baergic shareholders will receive $0.3M upfront, up to $2.5M in development/regulatory milestones, $79M in sales milestones, and tiered mid-to-high single-digit royalties.
- Avenue Therapeutics will receive ~74% of all future payments and royalties from the transaction.
More on Avenue Therapeutics, Axsome Therapeutics
- Axsome: Alzheimer's Disease Agitation sNDA Adds Optionality, Not A Thesis Changer
- Axsome Therapeutics, Inc. (AXSM) Q3 2025 Earnings Call Transcript
- Axsome Therapeutics, Inc. 2025 Q3 - Results - Earnings Call Presentation
- Axsome anticipates expanded market access for SYMBRAVO and AUVELITY while advancing late-stage pipeline
- Axsome Therapeutics GAAP EPS of -$0.94 misses by $0.07, revenue of $171M beats by $8.01M
推荐文章
新股申购 | 迅策、五一视界、英矽智能、美联股份、卧安机器人以及林清轩六只新股今起招股！
华盛早报 | 甲骨文融资告吹，重燃AI担忧带崩美股！纳指跌近2%；特朗普今日10点发声涉及26年政策
年末货币政策“压轴大戏”：欧洲四央行同日登场，仅一家有望降息？
评级巨头入局！穆迪拟推稳定币评级体系，锚定储备资产与赎回风险
壁仞科技冲击“港股GPU第一股”：手握总价超8亿的约束力订单
美光科技：AI领域存储器需求居高不下，公司营收预计大幅增长
12月18日外盘头条：美光科技公布强劲营收展望 亚马逊重组AI部门 美欲借新一轮制裁施压俄接受和平协议
华盛早报 | 全美讲话来袭！特朗普明日将预告明年新政；特斯拉大涨3%创历史新高
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
